Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: The Lira Pump trial-a randomized, double-blinded, placebo-controlled trial.
Thomas Fremming DejgaardSigne SchmidtChristian S FrandsenDorte VistisenSten MadsbadHenrik U AndersenKirsten NørgaardPublished in: Diabetes, obesity & metabolism (2019)
Liraglutide treatment reduced HbA1c, total daily insulin dose and body weight without increasing the risk of hypoglycaemia in CSII-treated patients with type 1 diabetes and insufficient glycaemic control. Liraglutide may be considered a potential add-on therapy to insulin in this subgroup of patients.
Keyphrases
- body weight
- type diabetes
- newly diagnosed
- glycemic control
- end stage renal disease
- physical activity
- study protocol
- ejection fraction
- chronic kidney disease
- prognostic factors
- weight loss
- clinical trial
- stem cells
- metabolic syndrome
- randomized controlled trial
- skeletal muscle
- weight gain
- combination therapy
- human health